share_log

Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double -- 6th Update

Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double -- 6th Update

輝瑞上調新冠肺炎疫苗預估銷售額增長逾一倍--第6次更新
Dow Jones Newswires ·  2021/11/02 21:06

By Jared S. Hopkins and Matt Grossman
賈裏德·S·霍普金斯和馬特·格羅斯曼著

Pfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.

輝瑞公司(Pfizer Inc.)將今年新冠肺炎疫苗的銷售額預期上調至約360億美元,增幅約為7%。與此同時,美國正準備向2,800萬名5至11歲的兒童發放疫苗。

The New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.

這家總部位於紐約的製藥商表示,其與合作伙伴BioNTech SE開發的疫苗的銷售預測考慮到了今年預計交付的約23億劑疫苗。這些公司已經提高了製造劑量的能力,並正在與海外其他公司合作生產劑量。

The vaccine's revenue of $13 billion was the biggest contributor to Pfizer's third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.

該疫苗130億美元的收入是輝瑞第三季度銷售額約240億美元的最大貢獻者,同比增長了一倍多。輝瑞首席執行長鮑拉(Albert Bourla)在財報電話會議上説,今年超過75%的疫苗銷售來自國際銷售,因為疫苗已經到達152個國家。

The vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.

在接受初始供應的國家和其他已經開始加強宣傳活動的國家,以及那些還沒有收到任何供應的國家,疫苗仍然是全球需求。美國已經批准為許多高危成年人額外注射疫苗,並於上週批准了對年僅5歲的兒童使用疫苗。

In the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency's endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.

在美國,由於美國疾病控制和預防中心(Centers For Disease Control And Prevention)週二晚間批准在兒童身上注射疫苗,預計最早將於週三在一些地方向幼兒提供疫苗。在美國食品和藥物管理局(Food and Drug Administration,簡稱FDA)上週批准在臨牀試驗之外使用疫苗後,FDA的認可是疫苗可以接種之前的最後一步。9月份,許多高危成年人獲得了疫苗的強化注射。

Pfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world's initial vaccine rollout, Mr. Bourla said in an interview.

輝瑞計劃明年生產約40億劑,但已獲得17億劑的訂單。鮑拉在接受採訪時説,訂單數量表明它正在滿足需求,低收入國家應該在富裕國家之前達成供應協議,以避免像它們在全球最初推出疫苗時那樣落後。

"We are already going way above what we forecast is needed based on the orders we have," Mr. Bourla said. "If there are orders we will make more next year."

“根據我們的訂單,我們已經遠遠超出了我們預測的需求量,”布拉説。“如果有訂單,我們明年就會有更多訂單。”

While data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.

輝瑞首席科學官米凱爾·多爾斯滕(Mikael Dolsten)在接受採訪時表示,雖然輝瑞和其他研究人員的數據顯示,額外的劑量可能會增強保護作用,但研究第四劑疫苗的試驗可能會在明年春天開始,也就是研究中的試驗對象接種第三劑疫苗大約一年後。

That could lead to study results in time for people to get a fourth dose when they get flu shots.

這可能會導致研究結果及時出現,以便人們在接種流感疫苗時獲得第四劑疫苗。

"It's really to prepare for what we think is the very likely need for annual revaccinations," he said.

他説:“這真的是在為我們認為很可能需要進行的年度複審做準備。”

The company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.

該公司最近表示,在一項大型研究中發現,第三劑新冠肺炎是安全的,對有症狀的新冠肺炎具有高度保護作用。

The vaccine's revenue of $13 billion was the biggest contributor to Pfizer's third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.

該疫苗130億美元的收入是輝瑞第三季度銷售額約240億美元的最大貢獻者,同比增長了一倍多。布拉説,今年超過75%的疫苗銷售來自國際銷售,因為疫苗已經到達152個國家。

Pfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck & Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.

輝瑞公司表示,預計其實驗性新冠肺炎抗病毒藥物的初步結果將於2022年第一季度末公佈,該藥物正處於後期測試階段。研究人員正在疫苗接種和未接種疫苗的人羣以及低風險人羣中研究這種藥物,這可能會將其與默克公司(Merck&Co.)和美國食品和藥物管理局(Food And Drug Administration)正在審查的Ridgeback BioTreateutics LP的一種有前途的抗病毒藥物區分開來。

The company has begun providing scientific data to the FDA, although it hasn't formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.

該公司已經開始向FDA提供科學數據,儘管它還沒有正式請求授權。鮑拉説,如果獲得授權,輝瑞今年將能夠提供劑量。

Pfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.

輝瑞生物製藥總裁安吉拉·黃(Angela Hwang)表示,輝瑞預計全球可能有多達1.5億成年人由於感染和密切接觸而需要抗病毒藥物。她説,有可能進行長期銷售,也有可能與政府簽訂儲備合同。

Pfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year's revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.

輝瑞預計,在17億劑的基礎上,明年的銷售額將達到290億美元,這反映了長期銷售的持久性,以及各國在冬季幾個月遏制病毒傳播的努力。布拉説,許多國家將購買兒科用藥。明年的營收可能更高,因為預估反映的是截至10月中旬簽署的供應協議。

Should the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world's top-selling prescription drug in recent years has been AbbVie Inc.'s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.

如果銷售成為現實,他們將使輝瑞-生物科技疫苗成為有史以來最暢銷的醫藥產品。近年來全球最暢銷的處方藥是艾伯維公司的抗炎藥Humira,該藥在2018年的銷售額接近200億美元。

Pfizer splits vaccine sales with BioNTech.

輝瑞與BioNTech平分疫苗銷售。

The outlook for Pfizer's vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.

輝瑞(Pfizer)疫苗的前景反映出,相對於競爭對手的疫苗,輝瑞對該疫苗的偏好程度更高。近2億美國人已經完全接種了疫苗,超過一半的人接受了輝瑞-生物科技(Pfizer-BioNTech)的注射。其餘的大多數人接種了來自現代公司的疫苗,該公司使用了類似的基於mRNA的技術。

Pfizer has also distributed two billion doses so far and is on track to produce three billion doses.

到目前為止,輝瑞公司也已經分發了20億劑,並正在按計劃生產30億劑。

Mr. Bourla in the interview urged poor countries to secure supply -- at discounted or not-for-profit prices -- for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.

布拉在接受採訪時敦促窮國以折扣價或非盈利性價格確保明年的供應,他希望避免重蹈它們落後於富裕國家的覆轍。他説,他希望世界衞生組織和Covax能提供幫助。

The Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.

Covax計劃由包括聯合國兒童基金會和世界衞生組織在內的多個組織運營,旨在為富國和窮國提供平等的疫苗接種機會。

Mr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.

布拉説,他已經致函各國要求他們下訂單,並説他們應該比過去更積極主動。

"Some governments are better than others," he said. "That's the problem."

他説:“一些政府比其他政府做得更好。”“這就是問題所在。”

Pfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.

輝瑞和其他疫苗製造商正面臨來自各國、公共衞生官員和藥物獲取倡導者的批評,因為它們沒有向低收入和中等收入國家提供足夠的劑量。一些國家缺乏與公司達成交易的資金,也缺乏自己動手的知識,迫使它們依賴於Covax計劃。有供應協議的國家也受到冷藏疫苗所需基礎設施不足的阻礙。

Only 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.

根據世界衞生組織的數據,低收入國家中只有3.7%的人接種了至少一劑新冠肺炎疫苗。一些批評人士建議政府放棄知識產權以刺激生產,這一想法遭到疫苗製造商的拒絕。

The Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.

輝瑞-生物科技疫苗預計很快就會在美國向5歲的兒童提供,上週美國衞生當局授權緊急使用該疫苗,作為這些年輕人的第一針新冠肺炎疫苗。該疫苗完全批准16歲及以上人羣使用,並允許12歲及以上兒童緊急使用。

U.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.

美國監管機構已經批准為接種輝瑞-生物技術疫苗的人提供增強劑,只要他們是老年人或由於潛在的醫療條件或工作場所的高風險,在接種第二劑疫苗至少六個月後就可以接種。自那以後,監管機構擴大了對接受莫迪納或強生疫苗的人的免疫接種範圍。

The Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.

輝瑞-生物科技(Pfizer-BioNTech)疫苗通過臨牀試驗和監管障礙的速度比獲準在成年人身上使用的競爭對手疫苗的速度更快。

Initial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.

多爾斯滕博士説,輝瑞生物科技(Pfizer-BioNTech)疫苗在2至4歲兒童中的臨牀研究的初步結果預計將於今年年底公佈,而6個月至2歲以下兒童的數據應會在下個季度末公佈。

Moderna said recently it won't seek approval for its vaccine's use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn't started studying it yet in younger children.

莫德納最近表示,在FDA批准青少年接種疫苗之前,它不會尋求批准其疫苗在幼兒中的使用。強生(音譯)是第三種獲準在美國使用的疫苗,他正在研究這種疫苗在青少年中的注射,但還沒有開始在年幼的兒童身上研究。

Pfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.

輝瑞還上調了今年的整體財務指引,預計銷售額為810億至820億美元,調整後每股收益為4.13美元至4.18美元。它將這一增長歸因於疫苗和非疫苗的勢頭。

Excluding the Covid-19 vaccine, sales of Pfizer's other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.

不包括新冠肺炎疫苗,輝瑞其他藥物的銷售額增長了7%.腫瘤藥物銷售額增長12%,超過30億美元,乳腺癌治療藥物Ibrance和前列腺癌藥物Xtandi的銷售額躍升。血液稀釋劑的收入增長了21%,超過13億美元。

Stripping out one-time items, the company's adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.

剔除一次性項目,該公司調整後的第三季度利潤為每股1.34美元。華爾街分析師此前預測營收為225.8億美元,調整後每股收益為1.08美元。

Write to Jared S. Hopkins at jared.hopkins@wsj.com and Matt Grossman at matt.grossman@wsj.com

寫信給賈裏德·S·霍普金斯(Jared S.Hopkins)(jared.Hopkins@wsj.com)和馬特·格羅斯曼(Matt Grossman)(matt.grossman@wsj.com)

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論